GH Research PLC

GH Research Plc operates as a holding company, which engages in the provision of biopharmaceutical products and services. It develops therapeutic products for patients of psychiatric and neurological disorders. The firm develops novel and proprietary 5-Methoxy-N and N-Dimethyltryptamine, or 5-MeO-DMT, therapies. The company was founded by Theis Terwey, Florian Schönharting, and Magnus Halle in 2018 and is headquartered in Dublin, Ireland.

Earnings data Q1 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

The average of price targets set by Wall Street analysts indicates a potential upside of 321.3% in GH Research PLC (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

How Much Upside is Left in GH Research PLC (GHRS)? Wall Street Analysts Think 321.28%

DUBLIN, Ireland, Feb. 29, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the year ended December 31, 2023, and provided updates on its business.

GH Research Reports Full Year 2023 Financial Results and Provides Business Updates

DUBLIN, Ireland, Jan. 18, 2024 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today announced that it recently received a communication from the European Patent Office (EPO) that it has been granted a patent with claims directed to mebufotenin (5-MeO-DMT) or a pharmaceutically acceptable salt thereof for use in treating patients diagnosed with major depressive disorder (MDD) and treatment-resistant forms of MDD, such as treatment-resistant depression (TRD).

GH Research Announces Grant of European Patent Covering all Mebufotenin (5-MeO-DMT) and Mebufotenin Salt Products For Use in the Treatment of Major Depressive Disorder and Treatment-Resistant Depression

The average of price targets set by Wall Street analysts indicates a potential upside of 488.7% in GH Research PLC (GHRS). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can GH Research PLC (GHRS) Climb 488.72% to Reach the Level Wall Street Analysts Expect?

DUBLIN, Ireland, Nov. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2023, and provided business updates.

GH Research Reports Third Quarter Financial Results and Provides Business Updates

ExScientia Ltd

Rithm Capital Corp

Arcadia Biosciences

RKDA, GHRS, GPS, RITM and EXAI have been added to the Zacks Rank #1 (Strong Buy) List on October 25, 2023.

New Strong Buy Stocks for October 25th

DUBLIN, Ireland, Sept. 29, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates and guidance on its clinical development program for GH001, its proprietary inhalable mebufotenin (5-MeO-DMT) product candidate, in treatment-resistant depression (TRD).

GH Research Provides Updates and Guidance on its Clinical Development Program for GH001 in Treatment-Resistant Depression

DUBLIN, Ireland, Aug. 23, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2023 and provided business updates.

GH Research Reports Second Quarter 2023 Financial Results and Provides Business Updates

COMPASS Pathways

Mind Medicine MindMed

Psychedelic stocks have a bright future with 13.5% compound annual growth expected through 2029. That growth will certainly draw in investment funding that seeks to capitalize on growth, as psychedelic drugs quickly  become a hot topic in the mental health space.

The 3 Best Psychedelic Stocks to Buy Now

GH Research PLC is developing mebufotenin, developed from toad venom, as an antidepressant. They have some early positive data. However, toad venom is a controlled substance and will face approval difficulties.

GH Research: But Toad Venom Is A Controlled Substance

DUBLIN, Ireland, May 11, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2023 and provided business highlights.

GH Research Reports First Quarter 2023 Financial Results and Provides Business Highlights

DUBLIN, Ireland, March 02, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the full year ended December 31, 2022 and gave updates on its business.

GH Research Reports Full Year 2022 Financial Results and Provides Business Updates

Atai Life Sciences BV

Cybin

Ameri Holdings

Advisorshares Psychedelics ETF

Psychedelic stocks have seen remarkable progress in recent years, evolving from a fad to mainstream medicine. Several pharmaceutical companies are now investigating their potential therapeutic value.

The 7 Most Promising Psychedelic Stocks to Buy in February

Stephen Tobin on investing in psychedelic stocks while they're still pre-revenue. Will first-movers get the advantage?

Psychedelic Sunday: Competitive Strategies

DUBLIN, Ireland, Jan. 09, 2023 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today provided updates on its business and highlighted key upcoming milestones.

GH Research Provides Business Updates and Highlights Key Upcoming Milestones

Gemini Therapeutics

Janux Therapeutics

Omega Flex

Polar Power

Red Violet

Via Renewables

Throughout much of the new normal, the concept of short-squeeze stocks took off like wildfire. Essentially, this tactic centers on taking a contrarian bet against bearish traders in Wall Street's version of playing chicken.

7 Short-Squeeze Stocks for Bold Contrarians to Consider

DUBLIN, Ireland, Nov. 10, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the third quarter ended September 30, 2022 and gave updates on its business.

GH Research Reports Third Quarter 2022 Financial Results and Provides Business Updates

The consensus price target hints at a 262% upside potential for GH Research PLC (GHRS). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.

Wall Street Analysts See a 262% Upside in GH Research PLC (GHRS): Can the Stock Really Move This High?

Psychedelics stocks are becoming increasingly mainstream, in part due to changing social attitudes. Psychedelic drugs “are a loosely grouped class of drugs that are able to induce altered thoughts and sensory perceptions.

7 Psychedelics Stocks to Buy for a Big Drug Boom

The mean of analysts' price targets for GH Research PLC (GHRS) points to a 205.8% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts Predict a 206% Upside in GH Research PLC (GHRS): Here's What You Should Know

DUBLIN, Ireland, Aug. 23, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the second quarter ended June 30, 2022 and gave updates on its business.

GH Research Reports Second Quarter 2022 Financial Results and Provides Business Updates

DUBLIN, Ireland, May 18, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the first quarter ended March 31, 2022 and gave updates on its business.

GH Research Reports First Quarter 2022 Financial Results and Provides Business Updates

DUBLIN, Ireland., March 28, 2022 (GLOBE NEWSWIRE) -- GH Research PLC (Nasdaq: GHRS), a clinical-stage biopharmaceutical company dedicated to transforming the treatment of psychiatric and neurological disorders, today reported financial results for the full year ended December 31, 2021 and gave updates on its business.

GH Research Reports Full Year 2021 Financial Results and Provides Business Updates

Revive Therapeutics (OTC:RVVTF) shares closed up 14.94% at $0.25 ATAI Life Sciences (NASDAQ:ATAI) shares closed up 3.53% at $5.58

Revive Therapeutics, GH Research Among Top Psychedelic Movers Of Today

The stock price of GH Research PLC (NASDAQ: GHRS) increased by 21.86% today. This is why it happened.

News for GH Research PLC Stock (GHRS)